- Home
- IMUX vs SOL Comparison
IMUX vs SOL Comparison
Compare IMUX & SOL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMUX
- SOL
- Stock Information
- Founded
- IMUX 2016
- SOL 2005
- Country
- IMUX United States
- SOL United States
- Employees
- IMUX N/A
- SOL N/A
- Industry
- IMUX Biotechnology: Pharmaceutical Preparations
- SOL Semiconductors
- Sector
- IMUX Health Care
- SOL Technology
- Exchange
- IMUX Nasdaq
- SOL Nasdaq
- Market Cap
- IMUX 100.0M
- SOL 104.0M
- IPO Year
- IMUX N/A
- SOL 2008
- Fundamental
- Price
- IMUX $0.95
- SOL $2.04
- Analyst Decision
- IMUX Strong Buy
- SOL Buy
- Analyst Count
- IMUX 6
- SOL 3
- Target Price
- IMUX $12.67
- SOL $3.83
- AVG Volume (30 Days)
- IMUX 991.0K
- SOL 277.9K
- Earning Date
- IMUX 02-20-2025
- SOL 11-14-2024
- Dividend Yield
- IMUX N/A
- SOL N/A
- EPS Growth
- IMUX N/A
- SOL N/A
- EPS
- IMUX N/A
- SOL N/A
- Revenue
- IMUX N/A
- SOL $102,489,000.00
- Revenue This Year
- IMUX N/A
- SOL N/A
- Revenue Next Year
- IMUX N/A
- SOL $46.42
- P/E Ratio
- IMUX N/A
- SOL N/A
- Revenue Growth
- IMUX N/A
- SOL 25.98
- 52 Week Low
- IMUX $0.95
- SOL $1.41
- 52 Week High
- IMUX $2.11
- SOL $3.00
- Technical
- Relative Strength Index (RSI)
- IMUX 36.31
- SOL 51.14
- Support Level
- IMUX $0.99
- SOL $1.86
- Resistance Level
- IMUX $1.05
- SOL $2.17
- Average True Range (ATR)
- IMUX 0.07
- SOL 0.14
- MACD
- IMUX -0.00
- SOL 0.00
- Stochastic Oscillator
- IMUX 1.50
- SOL 40.91
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
About SOL Emeren Group Ltd each representing 10 shares
Emeren Group Ltd is a renewable energy producer. Its portfolio consists of solar projects and Independent Power Producer (IPP) assets, and it also has global Battery Energy Storage System (BESS) capacity. The group specializes in the solar project lifecycle, development, and from construction to financing. It has three reportable segments; Solar power project development, EPC services, and Electricity generation. The company generates maximum revenue from Poland.